MedTrace Logo

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

NCT04541329 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2024-04-30

Study results available
· View outcomes & findings →

Summary

This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.

Conditions

  • Psoriasis Vulgaris

Interventions

BIOLOGICAL

Tildrakizumab

IL-23 inhibitor

Sponsors & Collaborators

Principal Investigators

  • Raymond Cho, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-16
Primary Completion
2023-01-15
Completion
2023-01-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04541329 on ClinicalTrials.gov